Paul A Decker

23PUBLICATIONS
166CO-AUTHORS
Haematological tumoursMedical biochemistry - inorganic elements and compoundsGene and molecular therapyGene expression (incl. microarray and other genome-wide approaches)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (23)

|May 04, 2026
MRI Deep Learning for Differentiating Glioblastoma, IDH Wild-type from Central Nervous System Diffuse Large B-cell Lymphoma.

|Mar 19, 2026
Cerebrospinal fluid D-2-hydroxyglutarate for IDH-mutant glioma monitoring.

Cecile Riviere-Cazaux, Yuta Suzuki, Zain Kizilbash

|Feb 10, 2026
Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenografts.

Rachael A Vaubel, Wenjuan Zhang, Nishika Karbhari

|Jul 25, 2025
Dissecting the biology of gliomagenesis: Evaluating the interaction between IDH tumor mutation and germline variants.

Matthew L Kosel, Paul A Decker, Thomas M Kollmeyer

|Jul 01, 2025
Preclinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH-Wild-type Glioblastoma.

Rachael A Vaubel, Wenjuan Zhang, Ju-Hee Oh

|Apr 15, 2025
The novel brain penetrant ataxia-telangiectasia mutated inhibitor WSD0628 provides robust radiosensitization of brain tumor patient-derived xenografts.

Zhiyi Xue, Ann C Mladek, Sneha Rathi

Pageof 4

Frequent Collaborators

11 joint publications

Jeanette E Eckel-Passow

10 joint publications

Jann N Sarkaria

6 joint publications

Brett L Carlson

6 joint publications

Danielle M Burgenske